Haemonetics upgraded to strong buy by Raymond James

peterschreiber.media Raymond James upgraded Haemonetics ( NYSE: HAE ) to strong buy from outperform, citing the company’s recent earnings report. “Despite the +11% reaction to FQ2 results, we have increased conviction that the core can sustain double-digit earnings growth and that the market continues to underappreciate the.